Biosimilar treatment for multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a biosimilar drug that acts like Ocrevus to treat multiple sclerosis. It aims to help manage disease activity and slow progression, and may be an option if you have relapsing or progressive MS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with relapsing or primary progressive multiple sclerosis (MS) as per the McDonald criteria.
- You have had recent MS disease activity.
- Your MS symptoms have been stable for at least 30 days before starting the study.
- Your disability level is within a certain range (measured by EDSS score), which varies by MS type.
- You are able to undergo MRI scans (no metal implants or other reasons you can't have an MRI).
- You do not have severe allergies to steroids like methylprednisolone.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study will follow people with multiple sclerosis (MS) who are starting or restarting a treatment called Ocrevus (ocrelizumab). The goal is to understand how well it works in real life over 12 months. Participants will receive Ocrevus as part of their usual care and complete surveys about their experience.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
This study compares how well two medicines, Kesimpta and Ocrevus, work for people with multiple sclerosis when used in real life. It looks at patient records to see which treatment might be more effective.
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
This extension study continues treatment with ocrelizumab for people with multiple sclerosis who are already taking it as part of a parent trial, to see how MS affects physical function over a longer time. It helps ensure you can keep receiving ocrelizumab even if it's not available where you live.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.